[Retrospective analysis of trastuzumab treatment in 141 @entity1 with @entity1722 positive XXXX ].

@entity1 @entity0 @entity4349 @entity3003 @entity1311 @entity3907 @entity1349 @entity1722
OBJECTIVE: To summarize the clinical experience of trastuzumab treatment in neoadjuvant, adjuvant, metastatic setting of Chinese @entity1 with @entity1722 positive @entity0 and evaluate the efficacy of trastuzumab in combination with chemotherapy. METHODS: From January 2004 to December 2008, 141 outpatients with @entity0 treated with trastuzumab were investigated retrospectively. The follow-up time ranged from 3 to 319 months. The disease free survival time (DFS) of metastatic setting was calculated. The @entity1349 ( @entity1349 ), time to treatment failure (TTF) and clinical response rate (CRR, including complete response, partial response and stable disease) of adjuvant, first-line, second-line therapy were analyzed statistically. RESULTS: In the neoadjuvant regimen, @entity1311 plus @entity3003 in combination with trastuzumab accounted for 66.7%, which achieved pathological complete response in 10 of 16 @entity1 . In the adjuvant regimen, @entity4349 or @entity4349 followed by @entity3907 accounted for 53.9%. The median DFS of 57 cases with metastatic diseases was 17 months. The CRR of first-line trastuzumab use in metastatic setting was 84.5%, compared with 44.4% of second-line use. The median TTF of first-line treatment was 24 months compared with 5 months of second-line treatment. Statistically significant differences were observed. CONCLUSION: The regimen of @entity1311 plus @entity3003 in combination with trastuzumab deserves wide clinical use. In metastatic setting, first-line treatment of trastuzumab plus chemotherapy can achieve a higher response rate than second-line treatment. Continued trastuzumab therapy combined with different chemotherapy treatment after disease progression may obtain additive clinical advantage.
